STOCK TITAN

Ardelyx Inc - ARDX STOCK NEWS

Welcome to our dedicated news page for Ardelyx (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ardelyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ardelyx's position in the market.

Rhea-AI Summary
Ardelyx, Inc. announced that Susan Rodriguez, chief commercial officer, will participate in a Cardiorenal panel discussion at the Cowen 44th Annual Health Care Conference. The event will take place on March 5, 2024, at 10:30 A.M. Eastern Time in Boston, MA. The live webcast will be accessible on the Ardelyx website, with a replay available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Ardelyx, Inc. reports strong commercial performance in FY 2023 with $80.1 million in net product sales revenue for IBSRELA and $2.5 million for XPHOZAH. The company ends FY 2023 with $184.3 million in cash and investments. Expectations for 2024 net product sales revenue are between $140.0 to $150.0 million. Key developments include expansion of IBSRELA sales team, initiation of a real-world evidence study for XPHOZAH, and release of the 2023 ESG report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
earnings
-
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) will hold a conference call on February 22, 2024, to discuss fourth quarter and full year 2023 financial results and provide a business update. Participants can join by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) and asking to be joined into the Ardelyx call. The live audio of the conference call will be webcast and available for replay for 30 days on the company's website at www.ardelyx.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
conferences earnings
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) granted new non-executive employees options to purchase 23,580 shares of the company's common stock and 33,300 Restricted Stock Units (RSUs) on January 10, 2024. Each stock option has an exercise price of $9.08 per share, with vesting over four years. The RSUs also vest over four years, with 25% vesting on the first anniversary of the employee's first day of employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) achieved significant commercial progress in 2023, with IBSRELA® expected to generate over $1.0 billion in annual U.S. net product sales revenue at peak. The company also saw a strong initial response to XPHOZAH® and finished 2023 with strong revenue performance, expecting IBSRELA to achieve greater than ten percent market share at peak. The company also had total cash, cash equivalents, and short-term investments of approximately $184 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.79%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) to Host Live Event and Webcast for IBSRELA® (tenapanor) Management Update and Key Opinion Leader Discussion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) announced on December 18, 2023, the granting of stock options and Restricted Stock Units (RSUs) to non-executive employees as inducements to enter into employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.54%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. (ARDX) announced the grant of options to purchase 221,805 shares of common stock and 182,068 Restricted Stock Units (RSUs) to non-executive employees, with an exercise price of $4.38 per share, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option vests over four years, and each RSU vests over four years with 25% vesting on the first anniversary of employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. (ARDX) to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference. The biopharmaceutical company aims to develop innovative medicines to address unmet medical needs. Management will discuss at 2:30 p.m. E.T. on November 29, 2023, in New York City. Webcast available on Ardelyx's Investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
conferences
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) announced that the FDA granted Orphan Drug Designation to XPHOZAH® (tenapanor) for pediatric hyperphosphatemia. XPHOZAH is a first-in-class medicine that blocks phosphate absorption. The designation supports the development of new drugs for rare diseases, providing potential market exclusivity for seven years after approval, exemption from user fees, and tax credits for qualified clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
clinical trial
Ardelyx Inc

Nasdaq:ARDX

ARDX Rankings

ARDX Stock Data

2.25B
226.59M
1.8%
59.46%
12.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Fremont

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.